News

News
iTeos_logo

GSK, iTeos take stock after Roche's TIGIT setback

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche'

News
Roche_labcoat

Roche's TIGIT ambitions take another blow

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste

News
Premature_baby

AZ, Sanofi build case for one-shot RSV antibody

A pooled analysis of data for AstraZeneca and Sanofi's respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respirat